Literature DB >> 23648668

SETBP1 mutation analysis in 944 patients with MDS and AML.

F Thol1, K J Suchanek, C Koenecke, M Stadler, U Platzbecker, C Thiede, T Schroeder, G Kobbe, S Kade, P Löffeld, S Banihosseini, G Bug, O Ottmann, W-K Hofmann, J Krauter, N Kröger, A Ganser, M Heuser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23648668     DOI： 10.1038/leu.2013.145

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  38 in total

1.  Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.

Authors:  Michiko Muraoka; Chiho Okuma; Kiichiro Kanamitsu; Hisashi Ishida; Yui Kanazawa; Kana Washio; Masafumi Seki; Motohiro Kato; Junko Takita; Yusuke Sato; Seishi Ogawa; Hirokazu Tsukahara; Megumi Oda; Akira Shimada
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

Review 2.  Next-generation sequencing-based panel testing for myeloid neoplasms.

Authors:  Frank C Kuo; Fei Dong
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

3.  Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Felicitas Thol; Michaela Scherr; Aylin Kirchner; Rabia Shahswar; Karin Battmer; Sofia Kade; Anuhar Chaturvedi; Christian Koenecke; Michael Stadler; Uwe Platzbecker; Christian Thiede; Thomas Schroeder; Guido Kobbe; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Nicolaus Kröger; Walter Fiedler; Richard Schlenk; Konstanze Döhner; Hartmut Döhner; Jürgen Krauter; Matthias Eder; Arnold Ganser; Michael Heuser
Journal:  Haematologica       Date:  2014-12-31       Impact factor: 9.941

4.  Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.

Authors:  M Heuser; M Meggendorfer; M M A Cruz; J Fabisch; S Klesse; L Köhler; G Göhring; C Ganster; K Shirneshan; A Gutermuth; S Cerny-Reiterer; J Krönke; V Panagiota; C Haferlach; C Koenecke; U Platzbecker; C Thiede; T Schroeder; G Kobbe; S Ehrlich; K Stamer; K Döhner; P Valent; B Schlegelberger; N Kroeger; A Ganser; D Haase; T Haferlach; F Thol
Journal:  Leukemia       Date:  2015-02-24       Impact factor: 11.528

Review 5.  Somatic SETBP1 mutations in myeloid neoplasms.

Authors:  Hideki Makishima
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

6.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.

Authors:  K Matsuda; Y Nakazawa; C Iwashita; T Kurata; K Hirabayashi; S Saito; M Tanaka; K Yoshikawa; R Yanagisawa; K Sakashita; S Sasaki; T Honda; K Koike
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

8.  Low frequency of calreticulin mutations in MDS patients.

Authors:  M Heuser; V Panagiota; C Koenecke; B Fehse; H Alchalby; A Badbaran; R Shahswar; M Stadler; M Eder; G Göhring; A Trummer; T Schroeder; G Kobbe; C Thiede; U Platzbecker; B Schlegelberger; N Kroeger; A Ganser; F Thol
Journal:  Leukemia       Date:  2014-05-21       Impact factor: 11.528

9.  SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.

Authors:  Emiliano Fabiani; Giulia Falconi; Luana Fianchi; Marianna Criscuolo; Giuseppe Leone; Maria Teresa Voso
Journal:  Haematologica       Date:  2014-06-06       Impact factor: 9.941

10.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.